Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
sharewise is moving On the weekend of 22/23 August the new sharewise becomes the main site. Have a look now and tell us what you miss. Go to the new sharewise What changes
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
buy

Regeneron Pharmaceuticals Inc. buy Wells Fargo & Company

Regeneron Pharmaceuticals Inc.
Start price
€519.00
30.04.25 / 50%
Target price
€615.65
30.04.26
Performance (%)
14.70%
End price
€595.30
01.05.26
Summary
This prediction ended on 01.05.26 with a price of €595.30. The prediction had a final performance of 14.70%. A total of €3.58 was paid as dividends for this prediction. Wells_Fargo___Compan has 50% into this prediction

Regeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.

AI-generated
Performance without dividends (%)
Name 1w 1m 1y
Regeneron Pharmaceuticals Inc. 2.374% 2.374% 39.972%
iShares Core DAX® 0,44 % 5,90 % 8,05 %
iShares Nasdaq 100 1,06 % 0,92 % 28,47 %
iShares Nikkei 225® 1,77 % 1,23 % 47,57 %
iShares S&P 500 0,37 % 1,92 % 23,20 %

Comments by Wells_Fargo___Compan for this prediction

In the thread Regeneron Pharmaceuticals Inc. diskutieren
Prediction Buy
Perf. (%) 14.70%
Target price 615.650
Change
Ends at 30.04.26

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at Wells Fargo & Company from $750.00 to $700.00. They now have an "overweight" rating on the stock.
Ratings data for REGN provided by MarketBeat

Wells Fargo & Company 
0
Report Share
30.04.25
In the thread Trading Regeneron Pharmaceuticals Inc.
Prediction Buy
Perf. (%) 14.70%
Target price 615.650
Change
Ends at 30.04.26

Die von Wells_Fargo___Compan gewählte maximale Laufzeit wurde überschritten

Wells Fargo & Company 
0
Report Share
01.05.26

Stopped prediction by Wells_Fargo___Compan for Regeneron Pharmaceuticals Inc.

buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€693.60
10.01.25
€875.97
10.01.26
-1.53%
11.01.26

Wells Fargo & Company 
10.01.25 50%
buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€995.60
23.09.24
€1,078.7
23.09.25
-51.79%
24.09.25

Wells Fargo & Company 
23.09.24 50%
buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€992.60
02.08.24
€1,099.3
02.08.25
-51.42%
03.08.25

Wells Fargo & Company 
02.08.24 50%